Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.23442 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Peripheral Artery Disease and Stroke.
J Cardiovasc Echogr
April 2020
Cardiology Department, Hospital 'Bianchi Melacrino Morelli' Reggio Calabria, Italy.
Peripheral artery disease (PAD) and stroke can occur as vascular complication of anticancer treatment. Although the mechanisms, monitoring, and management of cardiotoxicities have received broad attention, vascular toxicities remain often underrecognized. In addition, the development of new chemotherapeutic drugs bears the risk of vasotoxicities that are yet to be identified and may not be realized with short-term follow-up periods.
View Article and Find Full Text PDFAdherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital.
Int J Clin Pharm
February 2021
School of Pharmaceutical Sciences, Universiti Saints Malaysia, Gelugor, Penang, Malaysia.
Background Tyrosine kinase inhibitors have been demonstrated to improve the survival of patients with chronic myeloid leukaemia. However, medication adherence is vital for patients on chronic treatment. Objective The objective of the current study was to evaluate response to treatment, adherence by patients to tyrosine kinase inhibitors and factors associated with adherence and response.
View Article and Find Full Text PDFTyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement.
J Neurointerv Surg
November 2018
Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, US.
Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) has been associated with progressive peripheral arterial disease and, more recently, rare cases of intracranial vascular stenosis have been reported. We report the fourth case of TKI treatment associated intracranial vasculopathy and rapid progression of intracranial vascular stenosis following intracranial stent placement. This was a 49-year-old woman who developed right-sided weakness, paresthesias, numbness, and speech difficulties 7 years following TKI treatment for CML.
View Article and Find Full Text PDFIntracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
Interv Neuroradiol
October 2017
1 Department of Neurosurgery, Osaka International Cancer Institute, Japan.
One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!